Shanghai Huayi (SH:600623) HTSC·2025-08-11 15:00Investment Rating - The report initiates coverage on Huayi Group with an "Accumulate" rating and sets a target price of RMB 9.72, based on a 2025 PE of 18x [1][6]. Core Views - Huayi Group is a comprehensive chemical enterprise controlled by the Shanghai State-owned Assets Supervision and Administration Commission, with business segments including coal-based methanol/acetic acid, acrylic acid, tires, coatings, daily chemicals, and chemical services. The company's methanol/acetic acid/acrylic acid business is expected to benefit from price elasticity due to its scale advantages. With the ongoing state-owned enterprise reform, the continuous injection of quality assets from the controlling shareholder, such as San Aifu and Guangxi Energy Chemical, is likely to lead to a revaluation of the company's value [1][14]. Summary by Sections Company Overview - Huayi Group is a large chemical group controlled by the Shanghai State-owned Assets Supervision and Administration Commission, with a diversified business portfolio that includes coal-based methanol/acetic acid, acrylic acid, tires, coatings, daily chemicals, and chemical services. The company has a significant market presence in methanol and acetic acid production [19][22]. Production Capacity - The company has leading production capacities in methanol (1.61 million tons/year), acetic acid (1.3 million tons/year), and acrylic acid (720,000 tons/year), positioning it among the top in the industry. The expansion of MTO (Methanol to Olefins) and the impact of geopolitical conflicts on imported methanol supply may lead to a tight supply situation for methanol, while acetic acid and acrylic acid are expected to stabilize and recover in profitability [2][15]. Business Synergy and Asset Injection - The company has been enhancing its business synergy through the acquisition of quality assets from its controlling shareholder. The acquisition of a 60% stake in Shanghai Huayi San Aifu New Materials for RMB 4.09 billion has strengthened its position in the fluorochemical sector. The integration of various business segments is expected to improve operational efficiency and profitability [16][17]. Market Revaluation Potential - The company is currently trading below its book value (PB < 1), and with the ongoing state-owned enterprise reforms and the expected improvement in performance, there is potential for a revaluation of the company's market value. The continuous injection of quality assets from the controlling shareholder is anticipated to enhance the company's overall value [4][17][18]. Financial Projections - The report forecasts the company's net profit attributable to shareholders to be RMB 1.14 billion, RMB 1.38 billion, and RMB 1.56 billion for the years 2025, 2026, and 2027, respectively, representing year-on-year growth rates of 25%, 21%, and 13%. The corresponding EPS is projected to be RMB 0.54, RMB 0.65, and RMB 0.73 for the same years [6][11].